|
| |
|
| |
|
-- back to lectures --
|
| |
| Course Title: |
|
Reducing the Risk of Recurrence After Completion of Tamoxifen: Extended and Late Extended Adjuvant Therapy |
|
|
|
| |
| |
Credit Hours: |
0.5 |
| Valid Until: |
1/19/2011 |
|
| |
Lecturer: |
Karen Gelmon, MD |
|
Date Released: |
1/24/2009 |
|
| |
Affiliation: |
Department of Medical Oncology
British Columbia Cancer Agency
Vancouver, BC, Canada |
| |
|
| |
View the Post-Test
|
| |
|
| |
| |
Lecture Overview: |
| |
| |
Hormonal therapy is the first line of treatment for hormone receptor (HR)-positive breast cancer, which accounts for approximately two thirds of all breast cancers. The HR-positive breast cancers are characterized by dependence on estrogen for their growth. As a result, therapeutic strategies have been developed to inhibit hormone-mediated tumor growth. For over 25 years, the selective estrogen receptor modulator tamoxifen has been considered the gold standard in the hormonal treatment therapy of breast cancer. More recently, however, third-generation aromatase inhibitors/inactivators (AIs), potent agents that suppress estrogen production, are being integrated into adjuvant treatment regimens. Questions remain regarding the optimal strategy for utilizing AIs in the adjuvant setting, and clinical trials have investigated their timing and duration of use, as well as further characterizing their side-effect profiles and long-term impact on quality of life.
This CME activity will provide a comprehensive review of the latest advances in the use of hormonal therapies for the treatment of estrogen sensitive breast cancer, and discuss clinical challenges and applications. |
| |
|
| |
| |
Target Audience: |
| |
| |
This activity is intended for oncologists and other healthcare professionals who treat patients with breast cancer. |
| |
|
| |
| |
Objectives: |
| |
| |
Following this program, participants will be able to demonstrate the following improvements:- Weigh the benefits and risks of continuing adjuvant tamoxifen beyond 5 years
- Review the clinical data for use of aromatase inhibitors after completion of 5 years of tamoxifen
- Distinguish the relative benefits of extended and late-extended adjuvant therapy with aromatase inhibitors
- Identify safety considerations associated with initiating aromatase inhibitor therapy after completion of 5 years of tamoxifen
|
| |
|
| |
| |
Lecturer Disclosure Statement: |
| |
| |
It is the policy of Medical Education Conferences, Inc. (MEC) and Total CME to ensure balance, independence, objectivity, and scientific rigor in all CME activities. All faculty are asked to disclose any financial relations with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CME activity.
The following information was provided by each speaker:
Karen Gelmon, MD
Astra Zeneca: Advisory Board
Novartis: Speaker/Advisory Board
Pfizer: Advisory Board |
| |
|
| |
| |
Accreditation Statement: |
| |
| |
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Medical Education Conferences, Inc. and Total CME, Inc. Medical Education Conferences, Inc (MEC) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Medical Education Conferences, Inc. designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™ towards the AMA Physician Recognition Award. Each physician should claim only those hours of credit actually spent in the educational activity. |
| |
|
|
|
|
|
